Best Achievements in Pituitary and Adrenal Diseases in 2020

Abstract

Significant progress in pituitary and adrenal diseases was made in 2020. This review presents major translational and clinical advances in research on pituitary and adrenal diseases, encompassing their epidemiology, pathogenesis, diagnosis, and clinical management. We address the controversy regarding the nomenclature of pituitary neuroendocrine tumors, omics-based molecular classification of pituitary adenomas, and novel drugs for Cushing’s disease in the field of pituitary diseases. In the field of adrenal diseases, we cover big data-driven epidemiology of adrenal tumors, steroid profiling as a new diagnostic tool, and the utility of scoring systems in the decision-making process of managing primary aldosteronism. This brief article will broaden readers’ understanding of pituitary and adrenal diseases.

2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism

“…Steroid profiling is emerging as a promising new diagnostic tool in the decision-making process for managing PA [ 104 ]. The measurement of minor steroids (18-hydroxycorticosterone, [18OHB], 18-hydroxycortisol, [18OHF], and 18-oxo-cortisol, [18oxoF]) in the serum has been proposed as a way to distinguish PA subtypes.…”

Surgical management and outcomes of spinal metastasis of malignant adrenal tumor: A retrospective study of six cases and literature review

“…Adrenal tumor is a common disease seriously threatening people’s health, with the prevalence ranging from 1.0% to 8.7% with a mean of about 2% ( 1 , 2 ). About 1-12% patients with adrenal tumors are diagnosed with malignancy, mainly including adrenocortical carcinoma (ACC) from the adrenal cortex and malignant phaeochromocytoma (MP) from the adrenal medulla ( 3 , 4 ).…”